MECT与抑郁患者VEGF表达间相关性研究进展

Research Progress on the Correlation between MECT and VEGF Expression in Patients with Depression

抑郁症是临床最常见的精神疾病之一,给患者个人及社会带来巨大的疾病负担。抑郁症发病可能与神经营养因子功能失调所致的神经系统受损及神经功能异常有关,其中,血管内皮生长因子(vascular endothelial growth factor, VEGF)因具有成为抑郁症生物标志物的潜力被广泛研究。无抽搐电休克治疗(modified electroconvulsive therapy, MECT)可能通过调节VEGF表达影响神经元生长、血脑屏障通透性及突触可塑性,进而发挥抗抑郁作用。本文就MECT与抑郁患者VEGF表达间的相关性进行探讨,系统回顾和分析现有文献,旨在深入理解抑郁症的病理机制及MECT对神经系统的影响机制。

Depressive disorder is one of the most common mental illnesses in clinical practice, which brings a huge burden to patients and society. The onset of depressive disorder may be related to neurological damage and dysfunction caused by dysfunction of neurotrophic factors. Among them, vascular endothelial growth factor (VEGF) has been widely studied as a potential biomarker for depressive disorder. Modified electroconvulsive therapy (MECT) may exert antidepressant effects by regulating VEGF expression, affecting neuronal growth, blood-brain barrier permeability, and synaptic plasticity. This article explores the correlation between MECT and VEGF expression in patients with depressive disorder, systematically reviews and analyzes existing literature, aiming to gain a deeper understanding of the pathological mechanisms of depressive disorder and the impact of MECT on the nervous system.